REG - Ondine Biomedical - Director Holdings

Ondine BiomedicalAnnouncement

22/11/2024 08:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241122:nRSV2112Na&default-theme=true

RNS Number : 2112N  Ondine Biomedical Inc.  22 November 2024

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

 

Director Holdings

 

 

Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company pioneering
light-activated antimicrobial treatments, confirms that following admission of
the second tranche of new common shares at 8.00 a.m. on 22 November 2024 in
relation to the Fundraising, the directors' interests in the Company are as
follows:

 

 Director          Total number of common shares  % of issued share capital
 Carolyn Cross(1)  155,864,029                    38.58%
 Nicolas Loebel    3,513,991                      0.87%
 Junaid Bajwa      1,193,697                      0.30%
 Jean Duval        1,163,529                      0.29%
 Michael Farrar    484,806                        0.12%
 Jean Charest      353,356                        0.09%
 Margaret Shaw     213,853                        0.05%

(1) Existing beneficial holding includes 118,091,377 shares held by Carolyn
Cross, including via holdings in 100% owned companies, and 37,772,652 shares
held by Robert Cross, husband of Carolyn Cross.

 

 

-Ends-

 

Enquiries:

 

 Ondine Biomedical Inc.
 Angelika Vance, Corporate Communications  +001 604 838 2702
 Singer Capital Markets (Nominated Adviser & Joint Broker)
 Phil Davies, Sam Butcher                  +44 (0)20 7496 3000
 RBC Capital Markets (Joint Broker)
 Rupert Walford, Kathryn Deegan            +44 (0)20 7653 4000
 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard          +44 (0)77 1000 5910

 

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader
innovating light-activated antimicrobial therapies (also known as
'photodisinfection'). In addition to Steriwave, Ondine has a pipeline of
products, based on its proprietary photodisinfection technology, in various
stages of development.

 

Ondine's nasal photodisinfection system has a CE mark in Europe and the UK and
is approved in Canada and several other countries under the name
Steriwave(®). In the US, it has been granted Qualified Infectious Disease
Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns, and other
indications.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFSSLTLLFIS